ponatinib,blinatumomab
otsuka,incyte,astellas pharmaceuticals,amgen,takeda
['blinatumomab', 'ponatinib', 'leukemia']
#eha22 abstract s114: ponatinib and blinatumomab combination has high response rates for patients with philadelphia chromosome-positve acute lymphoblastic leukemia. our dr. nicholas short will present the findings on june 12: #endcancer
Driven by our mission to #EndCancer, MD Anderson is a leader in cancer care, research, education and training, and prevention. Appointments: 1-877-632-6789